Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RET-fusion Non Small Cell Lung Cancer”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Not applicableUnknownNCT04322591
What this trial is testing

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 70
Testing effectiveness (Phase 2)UnknownNCT05117658
What this trial is testing

Study of HA121-28 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 83
Early research (Phase 1)Active Not RecruitingNCT05241834
What this trial is testing

LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

Who this might be right for
Carcinoma, Non-Small-Cell LungThyroid Neoplasms
Eli Lilly and Company 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Not applicableNot Yet RecruitingNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT01639508
What this trial is testing

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Who this might be right for
Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 86
Testing effectiveness (Phase 2)Active Not RecruitingNCT05845671
What this trial is testing

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Who this might be right for
Lung CancerNon Small Cell Lung Cancer
University of Colorado, Denver 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04280081
What this trial is testing

Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Who this might be right for
Solid TumorMedullary Thyroid Cancer
Eli Lilly and Company 77
Testing effectiveness (Phase 2)Active Not RecruitingNCT03157128
What this trial is testing

Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+1 more
Eli Lilly and Company 857
Testing effectiveness (Phase 2)Active Not RecruitingNCT04268550
What this trial is testing

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Who this might be right for
Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
SWOG Cancer Research Network 124
Large-scale testing (Phase 3)Active Not RecruitingNCT04819100
What this trial is testing

Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company 152
Large-scale testing (Phase 3)Looking for participantsNCT06031558
What this trial is testing

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Shouyao Holdings (Beijing) Co. LTD 120
Testing effectiveness (Phase 2)UnknownNCT02540824
What this trial is testing

Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Tongji University 40
Early research (Phase 1)Study completedNCT03784378
What this trial is testing

Continued Access to RXDX-105

Who this might be right for
Non Small Cell Lung CancerOvarian CancerRET Gene Mutation+1 more
Memorial Sloan Kettering Cancer Center 3
Testing effectiveness (Phase 2)UnknownNCT05675605
What this trial is testing

TY-1091 in Patients With Advanced Solid Tumors

Who this might be right for
RET-altered Non Small Cell Lung CancerMedullary Thyroid CancerRET-altered Papillary Thyroid Cancer+1 more
TYK Medicines, Inc 248
Large-scale testing (Phase 3)Active Not RecruitingNCT04194944
What this trial is testing

Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Eli Lilly and Company 261
Not applicableLooking for participantsNCT04900935
What this trial is testing

Patient-centered, Optimal Integration of Survivorship and Palliative Care

Who this might be right for
Stage IV Non-small Cell Lung CancerTargeted TherapyNonsmall Cell Lung Cancer+5 more
Massachusetts General Hospital 70
Testing effectiveness (Phase 2)Ended earlyNCT04161391
What this trial is testing

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Who this might be right for
Non Small Cell Lung CancerMedullary Thyroid CancerRET Gene Mutation+2 more
Turning Point Therapeutics, Inc. 41
Not applicableNo Longer AvailableNCT05225259
What this trial is testing

Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

Who this might be right for
Carcinoma, Non-Small-Cell LungThyroid Neoplasms
Eli Lilly and Company
Testing effectiveness (Phase 2)UnknownNCT05278364
What this trial is testing

Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid CancerSolid Tumor
Shouyao Holdings (Beijing) Co. LTD 184
Load More Results